体外肝毒性评价细胞模型的研究进展

发布时间：2018-04-03 14:07

本文选题：肝细胞　切入点：D培养　出处：《中国新药杂志》2015年17期

【摘要】：药物性肝损伤是导致药物临床实验失败和上市后撤回的主要因素,而导致肝毒性药物进入临床实验的一个重要原因,是临床前动物模型与人类的种属差异。因此,开发新的临床前药物安全评价模型显得至关重要,临床前药物安全性评价模型中以人类肝细胞的体外培养为最可靠、快速、经济的模型。本文综述了在新药研发早期安全性评价中,不同体外模型的优点和不足之处,以期为药物安全性评价模型的进一步发展提供参考。
[Abstract]:Drug induced liver injury is the main factor leading to the failure and withdrawal of drugs in clinical trials, and the difference of species between preclinical animal models and human beings is one of the important reasons leading to the entry of hepatotoxic drugs into clinical trials.Therefore, it is important to develop a new pre-clinical drug safety evaluation model, in which human hepatocyte culture in vitro is the most reliable, rapid and economical model.This paper reviews the advantages and disadvantages of different in vitro models in the evaluation of drug safety in the early stage of new drug development in order to provide a reference for the further development of drug safety evaluation models.
【作者单位】：广东药学院药科学院;军事医学科学院毒物药物研究所抗毒药物与毒理学国家重点实验室(军事医学科学院)国家北京药物安全评价研究中心;
【基金】：国家“重大新药创制”科技重大专项(2013ZX09302303);国家“重大新药创制”科技重大专项(2012ZX09301003-001-008) 北京市科委基金(Z131100006513010)
【分类号】：R575

【相似文献】